1. Expression of CD133, E-cadherin and WWOX in colorectal cancer and related analysis
- Author
-
Wenyuan Gao, Lin Zhang, Li-Kui Qiao, Wen-Wen Sun, Na Shen, and Jin-Xia Dou
- Subjects
Oncology ,WWOX ,medicine.medical_specialty ,Lymphatic metastasis ,Tumor size ,business.industry ,Cadherin ,Colorectal cancer ,E-cadherin ,General Medicine ,medicine.disease ,Uicc stage ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Medicine ,Immunohistochemistry ,Original Article ,CD133 ,business ,Pathological ,030217 neurology & neurosurgery - Abstract
Objective: To detect the expression of CD133, E-cadherin and WWOX in colorectal cancer, analyze the correlations and pathological significance of the biomarkers. Methods: Two hundred and ten patients with colorectal cancer treated surgically between January 2007 and December 2015 were analyzed retrospectively. All patients had pathologic specimens and integrated clinical data. Pathologic specimens were retrieved for immunohistochemical examination of the expressions of CD133, WWOX and E-cadherin. The clinical data of these patients including gender, age, tumor location, tumor size, tumor differentiation, invasion depth, hepatic metastases, lymphatic metastasis, UICC stage and recurrence of tumor were retrieved to investigate their demographics and clinical characteristics. Results: In 210 specimens of colorectal cancer, the positive expression rate of CD133, E-cadherin and WWOX was 61.9%, 40.5% and 41.9%, respectively. The expression of CD133, E-cadherin and WWOX was significantly correlated with lymphatic metastasis, hepatic metastases and UICC stage (p
- Published
- 2017
- Full Text
- View/download PDF